Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Haloperidol decanoate
Drug ID BADD_D01055
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code Not Available
DrugBank ID Not Available
KEGG ID D01898
MeSH ID C033563
PubChem ID 52919
TTD Drug ID Not Available
NDC Product Code 72785-0007; 48292-0017; 0143-9296; 67457-410; 69766-070; 25021-831; 50458-253; 68001-580; 70069-030; 70710-1463; 68001-578; 70756-616; 70069-381; 70069-383; 72785-0004; 63323-471; 68083-138; 70518-3170; 71288-504; 17337-0519; 25021-833; 67457-409; 68001-579; 68001-581; 70069-384; 70518-1281; 71288-502; 71288-503; 10147-0921; 70710-1461; 70756-615; 72785-0006; 10147-0922; 68001-582; 68083-137; 70518-3743; 70710-1464; 70756-624; 50458-254; 63323-469; 70069-031; 72785-0005; 25021-834; 0143-9295; 70069-382; 70710-1462; 70756-625
UNII AC20PJ4101
Synonyms haloperidol decanoate
Chemical Information
Molecular Formula C31H41ClFNO3
CAS Registry Number 74050-97-8
SMILES CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Heat stroke24.06.02.009; 12.05.01.001--Not Available
Hepatic function abnormal09.01.02.001--Not Available
Hyperammonaemia14.10.01.001; 09.01.02.002--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperpyrexia08.05.02.002--Not Available
Hypertension24.08.02.001--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Insomnia17.15.03.002; 19.02.01.002--
Jaundice09.01.01.004; 23.03.03.030; 01.06.04.004--Not Available
Laryngospasm22.04.02.002--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Libido increased21.03.02.007; 19.08.03.002--
Menstruation irregular21.01.01.005; 05.05.01.008--
Monocytosis01.02.01.004--Not Available
Nausea07.01.07.001--
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Parkinsonism17.01.05.003--Not Available
Photosensitivity reaction23.03.09.003--
Priapism24.04.12.007; 21.03.01.005--Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Red blood cell count decreased13.01.05.007--Not Available
Respiratory depth increased22.02.01.022--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retinopathy06.10.02.001; 24.03.07.003--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages